EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieBeobachtungsstudie

Outcomes of drug-coated balloon angioplasty in patients with dyslipidemia in the BIOLUX P-III registry: A subgroup analysis

James Evan Dodd, Joseph Hanna, Marianne Brodmann, Jonathan Golledge, Thomas Zeller, Matej Moscovic, Johannes Dahm, Nicola Troisi, Gunnar Tepe, Jacqueline Wong, Natalie C Ward, Bibombe Patrice Mwipatayi iD

Vascular · 2025

DOI: 10.1177/17085381241275795 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Vascular, 2025. Verfasst von James Evan Dodd und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Surgery, Royal Perth Hospital, Perth, Australia. Hauptthemen laut MEDLINE: Angioplasty, Balloon, Cardiovascular Agents, Coated Materials, Biocompatible, Dyslipidemias. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Biotronik.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The aim of this study was to assess the mid-term outcomes of the use of drug-coated balloons (DCBs) to treat infrainguinal peripheral arterial disease (PAD) in patients with dyslipidemia.

Methods

BIOLUX P-III is a prospective, international, multicenter, all-comers registry-based study that was conducted at 44 sites with follow-ups at 6, 12 and 24 months. The present study is a subgroup analysis comparing the outcomes associated with endovascular revascularization with those associated with Passeo-18 lux DCBs in patients with and without dyslipidemia. The proportions of patients free from major adverse events (defined as device- or procedure-related mortality within 30 days, clinically driven target lesion revascularization (CD-TLR) and major target limb amputation), target vessel revascularization, and patient-reported outcomes within 24 months postintervention were compared between the two groups.

Results

A total of 876 patients with symptomatic PAD who underwent peripheral revascularization with DCBs and had information on their dyslipidemia status were included; 588 of those patients had dyslipidemia. There was no difference in the proportion of patients free from MAEs between the groups. The percentages of patients who were 6, 12 and 24 months free from CD-TLR were significantly lower in the dyslipidemia group than in the nondyslipidemia group (86.3% vs 91.9% at 2 years, p = .0183). Similarly, the percentage of patients free from target vessel revascularization was lower in the dyslipidemia group at all timepoints (83.3% vs 89.3% at 2 years, p = .0203). There was no difference in mortality or major or minor limb amputation rates. Other secondary outcomes were similar between the groups.

Conclusions

Compared to those without dyslipidemia, patients with symptomatic PAD and dyslipidemia who underwent revascularization with a Passeo-18 lux DCB had greater rates of CD-TLR and TVR. However, having dyslipidemia did not increase the risk of mortality or limb amputation. Clinical Trial Registration NCT02276313.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angioplasty, BalloonCardiovascular AgentsCoated Materials, BiocompatibleDyslipidemiasPeripheral Arterial DiseaseVascular Access DevicesAgedAged, 80 and overFemaleHumansMaleMiddle AgedAmputation, SurgicalEquipment DesignLimb SalvageLipidsProspective StudiesRegistriesRisk AssessmentRisk FactorsTime FactorsTreatment Outcome

Stichwörter der Autor:innen

Peripheral arterial diseaseangioplastydrug-coated balloondrug-eluting balloondyslipidemiastenosis

Substanzen

Cardiovascular AgentsCoated Materials, BiocompatibleLipids

Autor:innen und Institutionen

  • Department of Vascular Surgery, Royal Perth Hospital, Perth, Australia.
  • Department of Angiology, Medical University Graz, Graz, Austria.
  • Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, Australia.
  • The Department of Vascular and Endovascular Surgery, Townsville University Hospital, Townsville, Australia.
  • Clinic Cardiology and Angiology II, Universitäts-Herzzentrum Freiburg, Freiburg, Germany.
  • Department of Angiology, Institute of Cardiovascular Diseases, Kosice, Slovakia.

ORCID-Profile: Bibombe Patrice Mwipatayi

Förderung

  • Biotronik

Zitieren

APA

Dodd, J. E., Hanna, J., Brodmann, M., Golledge, J., Zeller, T., Moscovic, M., Dahm, J., Troisi, N., Tepe, G., Wong, J., Ward, N. C., & Mwipatayi, B. P. (2025). Outcomes of drug-coated balloon angioplasty in patients with dyslipidemia in the BIOLUX P-III registry: A subgroup analysis. Vascular. https://doi.org/10.1177/17085381241275795

Vancouver

Dodd JE, Hanna J, Brodmann M, Golledge J, Zeller T, Moscovic M, et al. Outcomes of drug-coated balloon angioplasty in patients with dyslipidemia in the BIOLUX P-III registry: A subgroup analysis. Vascular. 2025. doi:10.1177/17085381241275795

BibTeX
@article{Dodd2025,
  author = {Dodd, James Evan and Hanna, Joseph and Brodmann, Marianne and Golledge, Jonathan and Zeller, Thomas and Moscovic, Matej and Dahm, Johannes and Troisi, Nicola and Tepe, Gunnar and Wong, Jacqueline and Ward, Natalie C and Mwipatayi, Bibombe Patrice},
  title = {Outcomes of drug-coated balloon angioplasty in patients with dyslipidemia in the BIOLUX P-III registry: A subgroup analysis},
  journal = {Vascular},
  year = {2025},
  doi = {10.1177/17085381241275795}
}
Kostenlos starten →